{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:32:06Z","timestamp":1787236326137,"version":"build-2736575974"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006792","name":"Hartwell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cytogfr.2025.12.008","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T07:15:10Z","timestamp":1765782910000},"page":"102-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Interferons as therapeutic orchestrators of cancer stem cell plasticity and therapy response"],"prefix":"10.1016","volume":"87","author":[{"given":"Deepakshi","family":"Kasat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack D","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3531-4371","authenticated-orcid":false,"given":"Magalie","family":"Dosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2025.12.008_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","article-title":"Hallmarks of cancer stemness","volume":"31","author":"Loh","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.stem.2012.05.007","article-title":"Cancer stem cells: current status and evolving complexities","volume":"10","author":"Visvader","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.692940","article-title":"Cancer stem cells: emerging key players in immune evasion of cancers","volume":"9","author":"Lei","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tcb.2015.07.012","article-title":"Epithelial-mesenchymal plasticity: a central regulator of cancer progression","volume":"25","author":"Ye","year":"2015","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/cancers11040483","article-title":"Heterogeneity in circulating tumor cells: the relevance of the stem-cell subset","volume":"11","author":"Agnoletto","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrc3793","article-title":"Mechanisms of disseminated cancer cell dormancy: an awakening field","volume":"14","author":"Sosa","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib9","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1126\/science.aav0191","article-title":"How dormant cancer persists and reawakens","volume":"361","author":"Aguirre-Ghiso","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","article-title":"Cancer stem cells: landscape, challenges and emerging therapeutic innovations","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcell.2019.00016","article-title":"Meeting the challenge of targeting cancer stem cells","volume":"7","author":"Turdo","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib12","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1016\/j.cell.2025.06.044","article-title":"Interferons in health and disease","volume":"188","author":"Boehmer","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib15","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1038\/emboj.2013.203","article-title":"IFN\u03b2-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage","volume":"32","author":"Cheon","year":"2013","journal-title":"EMBO J."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib17","doi-asserted-by":"crossref","unstructured":"M.R. Doherty, H. Cheon, D.J. Junk, S. Vinayak, V. Varadan, M.L. Telli, J.M. Ford, G.R. Stark, M.W. Jackson, Interferon-beta represses cancer stem cell properties in triple-negative breast cancer, Proc. Natl. Acad. Sci. U. S. A. 2017114 pp. 13792\u201313797. https:\/\/doi.org\/10.1073\/pnas.1713728114..","DOI":"10.1073\/pnas.1713728114"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/0008-5472.CAN-18-2207","article-title":"IFN\u03b3-Induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via mirna processing","volume":"79","author":"Lo","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib19","doi-asserted-by":"crossref","unstructured":"H. Cheon, G.R. Stark, Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes, Proc. Natl. Acad. Sci. U. S. A, 2009106 pp.9373\u20139378. https:\/\/doi.org\/10.1073\/pnas.0903487106..","DOI":"10.1073\/pnas.0903487106"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib20","doi-asserted-by":"crossref","unstructured":"R.R. Weichselbaum, H. Ishwaran, T. Yoon, D.S.A. Nuyten, S.W. Baker, N. Khodarev, A.W. Su, A.Y. Shaikh, P. Roach, B. Kreike, B. Roizman, J. Bergh, Y. Pawitan, M.J. van de Vijver, A.J. Minn, An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer, Proc. Natl. Acad. Sci. U. S. A., 2008105 pp.18490\u201318495. https:\/\/doi.org\/10.1073\/pnas.0809242105..","DOI":"10.1073\/pnas.0809242105"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib22","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00262-019-02422-9","article-title":"ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression","volume":"68","author":"Burks","year":"2019","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib23","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1038\/s41467-020-16395-2","article-title":"ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity","volume":"11","author":"Alcal\u00e1","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib24","first-page":"182","article-title":"ISG15 and ISGylation modulates cancer stem cell-like characteristics in promoting tumor growth of anaplastic thyroid carcinoma","volume":"42","author":"Xu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib25","doi-asserted-by":"crossref","first-page":"41679","DOI":"10.1074\/jbc.M406413200","article-title":"Alternative activation of STAT1 and STAT3 in response to interferon-gamma","volume":"279","author":"Qing","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/BJ20050465","article-title":"STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells","volume":"392","author":"Bhattacharya","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-04-1752","article-title":"Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells","volume":"12","author":"Gritsko","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12964-020-0527-z","article-title":"Role of STAT3 signaling pathway in breast cancer","volume":"18","author":"Ma","year":"2020","journal-title":"Cell Commun. Signal. CCS"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cells9010217","article-title":"Role of JAK\/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial-mesenchymal transition","volume":"9","author":"Jin","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1083\/jcb.200812060","article-title":"Acetylation and activation of STAT3 mediated by nuclear translocation of CD44","volume":"185","author":"Lee","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1105166","article-title":"Stat3 dimerization regulated by reversible acetylation of a single lysine residue","volume":"307","author":"Yuan","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-030-40146-7_3","article-title":"Hyaluronan in the tumor microenvironment","volume":"1245","author":"Spinelli","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib33","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","article-title":"PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer","volume":"22","author":"Zhang","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48256-4","article-title":"Myeloid maturation potentiates STAT3-mediated atypical IFN-\u03b3 signaling and upregulation of PD-1 ligands in AML and MDS","volume":"9","author":"Yoyen-Ermis","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib35","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.cub.2005.08.036","article-title":"STAT5 contributes to interferon resistance of melanoma cells","volume":"15","author":"Wellbrock","year":"2005","journal-title":"Curr. Biol. CB"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib36","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/CMR.0b013e32830ce7d7","article-title":"STAT5 contributes to antiapoptosis in melanoma","volume":"18","author":"Hassel","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/mcbr.2000.0231","article-title":"STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells","volume":"3","author":"de Groot","year":"2000","journal-title":"Mol. Cell Biol. Res. Commun. MCBRC"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib38","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1182\/blood-2008-09-181107","article-title":"Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement","volume":"113","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib40","doi-asserted-by":"crossref","first-page":"9948","DOI":"10.1158\/0008-5472.CAN-06-1092","article-title":"Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition","volume":"66","author":"Lee","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib41","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/cancers11101428","article-title":"STAT3 and STAT5 activation in solid cancers","volume":"11","author":"Igelmann","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib42","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1128\/MCB.16.12.6937","article-title":"Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons","volume":"16","author":"Meinke","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib43","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2012-05-432906","article-title":"Interferon-\u03b3 impairs proliferation of hematopoietic stem cells in mice","volume":"121","author":"de Bruin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib44","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1158\/0008-5472.CAN-05-1387","article-title":"Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma","volume":"65","author":"Gollob","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib45","doi-asserted-by":"crossref","first-page":"28570","DOI":"10.1074\/jbc.M011685200","article-title":"The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells","volume":"276","author":"Mayer","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib46","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1074\/jbc.M309927200","article-title":"Role of p38alpha Map kinase in Type I interferon signaling","volume":"279","author":"Li","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib47","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1038\/s41388-022-02329-3","article-title":"Role of p38 MAP kinase in cancer stem cells and metastasis","volume":"41","author":"Kudaravalli","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib48","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1038\/onc.2016.203","article-title":"Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth","volume":"35","author":"Werden","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib49","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1016\/j.bbadis.2018.08.024","article-title":"Role of p38\u03b3 MAPK in regulation of EMT and cancer stem cells","volume":"1864","author":"Xu","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib50","first-page":"492","article-title":"Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma","volume":"47","author":"Roy","year":"2018","journal-title":"J. Oral. Pathol. Med. Off. Publ. Int. Assoc. Oral. Pathol. Am. Acad. Oral. Pathol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib51","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib52","doi-asserted-by":"crossref","first-page":"10069","DOI":"10.1073\/pnas.0703900104","article-title":"Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers","volume":"104","author":"Mani","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib53","doi-asserted-by":"crossref","first-page":"26702","DOI":"10.18632\/oncotarget.15804","article-title":"Inactivation of p38 MAPK contributes to stem cell-like properties of non-small cell lung cancer","volume":"8","author":"Fang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib54","doi-asserted-by":"crossref","first-page":"33316","DOI":"10.18632\/oncotarget.16741","article-title":"The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor trafficking","volume":"8","author":"Soeda","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib55","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1002\/cam4.1640","article-title":"Marine sponge-derived smenospongine preferentially eliminates breast cancer stem-like cells via p38\/AMPK\u03b1 pathways","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-020-0126-x","article-title":"WIP1 promotes cancer stem cell properties by inhibiting p38 MAPK in NSCLC","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib57","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1128\/MCB.19.11.7519","article-title":"Requirement for Ras\/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein","volume":"19","author":"Turkson","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib58","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1074\/jbc.M607674200","article-title":"A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes","volume":"282","author":"Gough","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib59","first-page":"70","article-title":"Inflammatory interferon activates HIF-1\u03b1-mediated epithelial-to-mesenchymal transition via PI3K\/AKT\/mTOR pathway","volume":"37","author":"Yeh","year":"2018","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib60","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.yexcr.2005.12.011","article-title":"Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway","volume":"312","author":"Fang","year":"2006","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cells5020016","article-title":"The NF-\u03baB Pathway and Cancer Stem Cells","volume":"5","author":"Rinkenbaugh","year":"2016","journal-title":"Cells"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib62","doi-asserted-by":"crossref","first-page":"13631","DOI":"10.1073\/pnas.250477397","article-title":"IFNalpha\/beta promotes cell survival by activating NF-kappa","volume":"97","author":"Yang","year":"2000","journal-title":"B Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib63","doi-asserted-by":"crossref","first-page":"31530","DOI":"10.1074\/jbc.M503120200","article-title":"Interferon induces NF-kappa B-inducing kinase\/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival","volume":"280","author":"Yang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2021.05.006","article-title":"Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression","volume":"514","author":"Provance","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib65","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/stem.1388","article-title":"IFN-\u03b3 and TNF-\u03b1 synergistically induce mesenchymal stem cell impairment and tumorigenesis via NF\u03baB signaling","volume":"31","author":"Wang","year":"2013","journal-title":"Stem Cells Dayt. Ohio"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123410","article-title":"Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-\u03baB","volume":"10","author":"Gowrishankar","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib67","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41388-022-02561-x","article-title":"Interferon-gamma signaling promotes melanoma progression and metastasis","volume":"42","author":"Zhou","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib68","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2013.04.029","article-title":"IFN-\u03b3 selectively exerts pro-apoptotic effects on tumor-initiating label-retaining colon cancer cells","volume":"336","author":"Ni","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib69","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1476-4598-13-132","article-title":"USP18 is crucial for IFN-\u03b3-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity","volume":"13","author":"Hong","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib70","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/s12885-018-4389-3","article-title":"Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells","volume":"18","author":"Morrison","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib71","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1158\/0008-5472.CAN-19-0596","article-title":"Low-Dose IFN\u03b3 induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib72","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/1440-1681.12732","article-title":"Increased PD-L1 expression in breast and colon cancer stem cells","volume":"44","author":"Wu","year":"2017","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib73","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3958908","article-title":"PD-L1 expression in human breast cancer stem cells is epigenetically regulated through posttranslational histone modifications","volume":"2019","author":"Darvin","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib74","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1404212","article-title":"Identification and editing of stem-like cells in methylcholanthrene-induced sarcomas","volume":"8","author":"Gross","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib75","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41590-022-01290-3","article-title":"Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B","volume":"23","author":"Musella","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib76","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.yexcr.2014.03.020","article-title":"Influence of interferon-\u03b1 on the expression of the cancer stem cell markers in pancreatic carcinoma cells","volume":"324","author":"Zhu","year":"2014","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib77","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.7150\/jca.19486","article-title":"Interferon-\u03b1 Promotes the Expression of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma","volume":"8","author":"Ma","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib78","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.3390\/cancers13215284","article-title":"Intrinsic interferon signaling regulates the cell death and mesenchymal phenotype of glioblastoma stem cells","volume":"13","author":"Khan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib79","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.celrep.2017.02.037","article-title":"CD95\/Fas increases stemness in cancer cells by inducing a STAT1-dependent type I interferon response","volume":"18","author":"Qadir","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022200","article-title":"USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon \u03b1 response","volume":"6","author":"Fran\u00e7ois-Newton","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib81","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3892\/ijo.2015.3165","article-title":"Antitumorigenic effect of interferon-\u03b2 by inhibition of undifferentiated glioblastoma cells","volume":"47","author":"Yamamuro","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib82","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1074\/jbc.R116.774562","article-title":"The molecular basis for differential type I interferon signaling","volume":"292","author":"Schreiber","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib83","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.3390\/cancers13215284","article-title":"Intrinsic interferon signaling regulates the cell death and mesenchymal phenotype of glioblastoma stem cells","volume":"13","author":"Khan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib84","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1158\/1078-0432.CCR-06-3092","article-title":"Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells","volume":"13","author":"Lesinski","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib85","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12307-010-0041-8","article-title":"Mesenchymal stem cells overexpressing IFN-\u03b2 inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic tumor model, cancer microenviron","volume":"3","author":"Ling","year":"2010","journal-title":"Off. J. Int. Cancer Microenviron. Soc."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib86","article-title":"Interferon receptor trafficking and signaling: journey to the cross roads","volume":"11","author":"Zanin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/embj.201283326","article-title":"PIAS1 SUMO ligase regulates the self-renewal and differentiation of hematopoietic stem cells","volume":"33","author":"Liu","year":"2014","journal-title":"EMBO J."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib88","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/1878-0261.12034","article-title":"TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3","volume":"11","author":"Zhang","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib89","article-title":"PIAS family in cancer: from basic mechanisms to clinical applications","volume":"14","author":"Li","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib90","doi-asserted-by":"crossref","DOI":"10.1111\/nan.13016","article-title":"Microglia induce an interferon-stimulated gene expression profile in glioblastoma and increase glioblastoma resistance to temozolomide","volume":"50","author":"S\u00f8rensen","year":"2024","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib91","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1158\/0008-5472.CAN-19-0596","article-title":"Low-dose IFN\u03b3 induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib92","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.stem.2023.05.007","article-title":"IFN\u03b3-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy","volume":"30","author":"Beziaud","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib93","first-page":"321","article-title":"Regulation of cancer stem cells in triple negative breast cancer","volume":"4","author":"Fultang","year":"2021","journal-title":"Cancer Drug Resist. Alhambra Calif."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib94","unstructured":"E. Centofanti, C. Wang, S. Iyer, O. Krichevsky, A. Oyler-Yaniv, J. Oyler-Yaniv, The spread of interferon-\u03b3 in melanomas is highly spatially confined, driving nongenetic variability in tumor cells, Proc. Natl. Acad. Sci. U. S. A, 2023120 e2304190120. https:\/\/doi.org\/10.1073\/pnas.2304190120.."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib95","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/0008-5472.CAN-23-4022","article-title":"Lineage Tracing and Single-Cell RNA sequencing reveal a common transcriptional state in breast cancer tumor-initiating cells characterized by IFN\/STAT1 activity","volume":"85","author":"Souto","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib96","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1038\/s41598-024-82218-9","article-title":"TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms","volume":"15","author":"Calistri","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib97","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41419-018-0399-y","article-title":"ELF3 promotes epithelial-mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma","volume":"9","author":"Zheng","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib98","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3892\/ijmm.2024.5418","article-title":"FOSL1 promotes stem cell\u2011like characteristics and anoikis resistance to facilitate tumorigenesis and metastasis in osteosarcoma by targeting SOX2","volume":"54","author":"Wang","year":"2024","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib99","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12967-025-06304-w","article-title":"FOSL1 drives the malignant progression of pancreatic cancer cells by regulating cell stemness, metastasis and multidrug efflux system","volume":"23","author":"Liu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94072-0","article-title":"The role of FOSL1 in stem-like cell reprogramming processes","volume":"11","author":"Pecce","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib101","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13036-023-00333-z","article-title":"The ELF3 transcription factor is associated with an epithelial phenotype and represses epithelial-mesenchymal transition","volume":"17","author":"Subbalakshmi","year":"2023","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102316","article-title":"Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer","author":"Afenteva","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib103","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib104","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12967-024-06023-8","article-title":"PD-L1 and IFN-\u03b3 modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)","volume":"23","author":"Angelicola","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cytogfr.2014.12.006","article-title":"Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use","volume":"26","author":"Antonelli","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib106","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00432-008-0453-8","article-title":"Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro","volume":"135","author":"Schmidt-Hieber","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib107","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.978","article-title":"The driver role of JAK-STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer","volume":"12","author":"Lo","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib108","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-22-0744","article-title":"STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer","volume":"28","author":"Qureshy","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib109","doi-asserted-by":"crossref","first-page":"24304","DOI":"10.18632\/oncotarget.24368","article-title":"Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer","volume":"9","author":"Han","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cytogfr.2025.12.008_bib110","article-title":"Niche modulation of IGF-1R signaling: its role in stem cell pluripotency, cancer reprogramming, and therapeutic applications","volume":"8","author":"Chen","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib111","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41419-021-04297-0","article-title":"Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade","volume":"12","author":"Han","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cytogfr.2025.12.008_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1249330","article-title":"Combining PD-1\/PD-L1 blockade with type I interferon in cancer therapy","volume":"14","author":"Razaghi","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:12:42Z","timestamp":1773933162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610125001662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":112,"alternative-id":["S1359610125001662"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.12.008","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferons as therapeutic orchestrators of cancer stem cell plasticity and therapy response","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}